MMP9 and breast carcinoma: The activity of MMP-2 and MMP-9 in serum or plasma, measured by gelatine zymography, has been shown to distinguish between breast cancer subclassification and various risk factors, predict lymph node metastasis, and evaluate treatment response in breast cancer patients.